Cellectar Biosciences reported a case study where a heavily pretreated patient with aggressive diffuse large B-cell lymphoma (DLBCL) achieved a durable complete response lasting over eight years after a single dose of iopofosine I 131. This treatment showed significant tumor reduction and no disease progression without additional therapy. The results support iopofosine's targeted mechanism and potential across B-cell cancers, complementing positive data in Waldenström macroglobulinemia. Cellectar plans to advance Phase 3 trials and seek accelerated FDA approval in 2027.
The case study on iopofosine I 131 in DLBCL patients is presented here alongside Pluang's health sector market data. As of Oct 27, 2026 17:43 WIB, 69 out of 150 health-sector US stocks rose while 68 fell. Notable movers include BNGO at USD 1.12 with a 3.45% decline and 100% sell order activity, CRON at USD 3.41 with a 3.02% gain, and ALMS at USD 6.70 with a 2.92% increase.
Black Ore introduced Black Ore for Small Firms, an AI-powered tax automation platform designed for small to mid-sized accounting practices. It integrates with Intuit tax software, enabling firms to handle more clients without increasing staff by auto...
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
